LINC02210-CRHR1: A Potential Drug Target and Biomarker (G104909134)

Target Name: LINC02210-CRHR1

NCBI ID: G104909134

LINC02210-CRHR1

LINC02210-CRHR1: A Potential Drug Target and Biomarker

Corticotropin-releasing factor (CRF) is a protein that plays a crucial role in the regulation of synaptic transmission between dopaminergic neurons within the fasciculata tract. Synaptic transmission between neurons is crucial in the normal function of the nervous system, and CRF plays a crucial role in regulating this process. However, the abnormal expression of CRF in various neurological diseases has also attracted the attention of scientists. Among them, abnormal expression of CRF in CRH-positive presynaptic neurons is a significant feature of depression.

In recent years, researchers have discovered that variations in the CRH gene are closely related to the occurrence of depression. LINC02210-CRHR1 is the coding region of the CRH gene, and its variation may be related to the onset of depression. Therefore, LINC02210-CRHR1 becomes a potential drug target.

In addition, LINC02210-CRHR1 mutations are associated with the onset of Alzheimer's disease. The LINC02210-CRHR1 mutation is prevalent in Alzheimer's disease patients. This also suggests that LINC02210-CRHR1 may play an important role in the occurrence of Alzheimer's disease.

In addition to mutations associated with neurological disease, mutations in LINC02210-CRHR1 are also associated with tumorigenesis. Studies have found that mutations in LINC02210-CRHR1 are related to the occurrence of various tumors, including lung cancer, liver cancer, breast cancer, etc. These findings indicate that LINC02210-CRHR1 mutations may be related to tumorigenesis, and its detection has important clinical significance for tumor diagnosis and treatment.

In addition to the above diseases, LINC02210-CRHR1 mutations are also related to mental health. The study found that the variation of LINC02210-CRHR1 is related to mental health status, and the degree of variation is positively correlated with the degree of mental health. This also shows that LINC02210-CRHR1 has a potential role in mental health.

In summary, LINC02210-CRHR1 is a potential drug target, and its mutations are associated with multiple neurological diseases, tumorigenesis, and mental health conditions. In-depth study of LINC02210-CRHR1 can provide an important theoretical basis for the diagnosis and treatment of related diseases.

Protein Name: LINC02210-CRHR1 Readthrough

Functions: G-protein coupled receptor for CRH (corticotropin-releasing factor) and UCN (urocortin). Has high affinity for CRH and UCN. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and down-stream effectors, such as adenylate cyclase. Promotes the activation of adenylate cyclase, leading to increased intracellular cAMP levels. Inhibits the activity of the calcium channel CACNA1H. Required for normal embryonic development of the adrenal gland and for normal hormonal responses to stress. Plays a role in the response to anxiogenic stimuli

The "LINC02210-CRHR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02210-CRHR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets